(NUVL) Nuvalent - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6707031075

Stock: Ros1 Inhibitor, Alk Inhibitor, Her2 Inhibitor

Total Rating 41

Risk 67

Buy Signal -0.53

Biotechnology » Biotechnology
Age: 4.5y

Market Cap: 7,481m
Avg Trading Vol: 53.1M USD

ATR: 4.81%
Peers RS (IBD): 37.50

EPS (Earnings per Share)

EPS CAGR: 6.29%
EPS Trend: -53.7%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 89.54%
Rev. Trend: 42.0%

Last SUE: 0.00
Qual. Beats: 0

Risk 5d forecast
Volatility	47.5%
Relative Tail Risk	-4.86%

Reward TTM
Sharpe Ratio	0.53
Alpha	1.68

Character TTM
Beta	0.924
Beta Downside	0.527

Drawdowns 3y
Max DD	47.12%
CAGR/Max DD	1.15

Description: NUVL Nuvalent January 09, 2026

Nuvalent Inc. (NASDAQ:NUVL) is a clinical-stage biopharma based in Cambridge, MA, focused on next-generation, brain-penetrant tyrosine-kinase inhibitors (TKIs) for oncogenic drivers that commonly develop resistance and central-nervous-system (CNS) complications.

Its lead candidates are:

NVL-520: a ROS1-selective inhibitor currently in the Phase 2 portion of the ARROS-1 trial, targeting ROS1-positive non-small-cell lung cancer (NSCLC) patients who face resistance and brain metastases. ROS1 rearrangements occur in ~1-2% of NSCLC (~10 k patients annually in the U.S.), representing a niche but high-unmet-need market.
NVL-655: a brain-penetrant ALK inhibitor in Phase 2 (ALKOVE-1), designed to overcome resistance and CNS toxicity seen with earlier-generation ALK TKIs. ALK alterations affect ~5% of NSCLC (~30 k U.S. patients), and CNS metastases are present in >30% of advanced cases.
NVL-330: a HER2-exon 20-selective, brain-penetrant inhibitor in Phase 1a/1b, aimed at HER2-driven tumors (including HER2-mutant NSCLC) where off-target EGFR inhibition drives dose-limiting toxicities. HER2-exon 20 mutations represent ~2% of NSCLC (~10 k patients) and have limited targeted options.

Financially, Nuvalent reported cash and cash equivalents of roughly **$140 million** in its latest 10-Q (Q2 2024), giving it a runway into 2026 at its current burn rate of ~**$30 million per year**. The company raised **$150 million** in a 2023 private placement, underscoring investor confidence in its CNS-penetrant strategy, a sector trend where biotech firms have seen an average 8% YoY increase in R&D spend and premium valuation multiples for late-stage oncology assets.

Given the modest prevalence but high unmet need of ROS1, ALK, and HER2-ex20 driven NSCLC, Nuvalent’s focus on CNS-active, resistance-bypassing TKIs aligns with a broader market shift toward precision oncology therapies that can address brain metastases-a key driver of overall survival and quality of life.

For a deeper, data-driven valuation of Nuvalent’s pipeline and cash runway, the ValueRay platform offers a concise analyst-grade model worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.27 > 0.02 and ΔFCF/TA -14.04 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.27 > 3% & CFO -263.9m > Net Income -381.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.73 > 1.5 & < 3
Outstanding Shares: last quarter (72.1m) vs 12m ago 9.84% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -1.53 > 6 (EBITDA TTM -408.0m / Interest Expense TTM 22.0m)

Altman Z'' -3.89

A: 0.89 (Total Current Assets 956.9m - Total Current Liabilities 89.2m) / Total Assets 979.9m
B: -0.87 (Retained Earnings -853.7m / Total Assets 979.9m)
C: -0.03 (EBIT TTM -33.7m / Avg Total Assets 1.08b)
D: -6.33 (Book Value of Equity -851.3m / Total Liabilities 134.5m)
Altman-Z'' Score: -3.89 = D

What is the price of NUVL shares?

As of February 08, 2026, the stock is trading at USD 103.59 with a total of 566,516 shares traded.
Over the past week, the price has changed by +0.68%, over one month by +6.57%, over three months by +8.05% and over the past year by +19.48%.

Is NUVL a buy, sell or hold?

Nuvalent has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy NUVL.

StrongBuy: 8
Buy: 3
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NUVL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	141.7	36.8%
Analysts Target Price	141.7	36.8%
ValueRay Target Price	143	38.1%

NUVL Fundamental Data Overview February 03, 2026

P/B = 9.4513
Revenue TTM = 0.0 USD
EBIT TTM = -33.7m USD
EBITDA TTM = -408.0m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -115.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.54b USD (7.48b + (null Debt) - CCE 943.1m)
Interest Coverage Ratio = -1.53 (Ebit TTM -33.7m / Interest Expense TTM 22.0m)
EV/FCF = -24.78x (Enterprise Value 6.54b / FCF TTM -263.9m)
FCF Yield = -4.04% (FCF TTM -263.9m / Enterprise Value 6.54b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 6.67 (Enterprise Value 6.54b / Total Assets 979.9m)
Interest Expense / Debt = unknown (Interest Expense 10.2m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -26.6m (EBIT -33.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.73 (Total Current Assets 956.9m / Total Current Liabilities 89.2m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.28 (negative EBITDA) (Net Debt -115.8m / EBITDA -408.0m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -115.8m / FCF TTM -263.9m)
Total Stockholder Equity = 966.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.18% (Net Income -381.4m / Total Assets 979.9m)
RoE = -39.47% (Net Income TTM -381.4m / Total Stockholder Equity 966.5m)
RoCE = -3.78% (EBIT -33.7m / Capital Employed (Total Assets 979.9m - Current Liab 89.2m))
RoIC = -2.76% (negative operating profit) (NOPAT -26.6m / Invested Capital 966.5m)
WACC = 9.32% (E(7.48b)/V(7.48b) * Re(9.32%) + (debt-free company))
Discount Rate = 9.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.71%
Fair Price DCF = unknown (Cash Flow -263.9m)
EPS Correlation: -53.73 | EPS CAGR: 6.29% | SUE: 4.0 | # QB: 1
Revenue Correlation: 42.01 | Revenue CAGR: 89.54% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.45 | Chg30d=+0.000 | Revisions Net=-4 | Analysts=8
EPS next Year (2026-12-31): EPS=-5.60 | Chg30d=+0.024 | Revisions Net=+2 | Growth EPS=-1.9% | Growth Revenue=+0.0%

Additional Sources for NUVL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle